Structure Therapeutics Inc. ADR advanced stock charts by Barron's. View GPCR historical stock data and compare to other stocks, and exchanges.
A multinational research team has revealed how a tryptophan-rich allosteric communication network regulates receptor dynamics ...
Structure Therapeutics advances oral therapies for diabetes, obesity, and pulmonary disease through its clinical-stage drug pipeline.
LifeSci Capital analyst Patrick Dolezal maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR today and set a price target of $107.00. Dolezal covers the Healthcare sector, focusing on ...
A multinational research team led by researchers at Institute of Science Tokyo, RIKEN, and the University of Toronto has ...
Commercial sales and marketing agreement enhances 3RnD’s mechanistic toxicity screening panel, and expands the reach of ...
Detailed price information for Voyager Therapeut (VYGR-Q) from The Globe and Mail including charting and trades.
Structure Therapeutics (NASDAQ:GPCR) shared new top-line results from its ACCESS II clinical program for aleniglipron, an ...
Structure Therapeutics said its experimental pill helped people lose about 16% of their body weight after about a year of treatment Structure Therapeutics is one of several companies developing new ...
Structure Therapeutics stock jumped 5.4%, closing at $56.65 on Monday, when it touted 16% weight loss - about 39 pounds – demonstrated by aleniglipron as the best results yet for an oral GLP-1 drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results